PSMA PET/CT imaging for biochemical recurrence of prostate cancer after radiotherapy: is it necessary to review the Phoenix criteria?



PSMA positron emission tomography (PET)/CT imaging and new systemic treatment strategies have been recently implemented in the routine care of patients with prostate cancer. In the new era of PSMA PET/CT imaging, the definition of recurrence as established by the Phoenix criteria may be questioned.



The development of PSMA PET/CT questions the need for a review of the Phoenix criteria. Solid studies are needed to evaluate new PSA thresholds to redefine these criteria considering the clinical benefit to the patient of changing the therapeutic approach at different stages of the disease.